Lab. ofThermo-therapeutics for vascular dysfunction

Osaka University Graduate School of Medicine

Publications

  1. Shima Y, Watanabe A, Inoue N, Maruyama T, Kunitomo E, Kumanogoh A. Heating of the neck or elbows alleviates Raynaud's phenomenon but has different effects on different types of patients with systemic sclerosis. Mod Rheumatol. 2023; 14:road091.
  2. Konaka H, Kato Y, Hirano T, Tsujimoto K, Park J, Koba T, Aoki W, Matsuzaki Y, Taki M, Koyama S, Itotagawa E, Jo T, Hirayama T, Kawai T, Ishii KJ, Ueda M, Yamaguchi S, Akira S, Morita T, Maeda Y, Nishide M, Nishida S, Shima Y, Narazaki M, Takamatsu H, Kumanogoh A.　Secretion of mitochondrial DNA via exosomes promotes inflammation in Behçet's syndrome. EMBO J. 2023; 16;42(20):e112573
  3. Kuwana M, Takehara K, Tanaka Y, Yamashita K, Katsumata K, Takata M, Shima Y. Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial. Mod Rheumatol. 2023; 4:road068.
  4. Makimoto K, Shiozawa K, Shima Y, Hirano T, Inoue M, Understanding Patients’ Symptoms Management Using Objective and Subjective Indicators among Patients with Systemic Lupus Erythematosus. Open Journal of Nursing, 2023; 13: 314-328
  5. Inoue M, Shiozawa K, Yoshihara R, Shima Y, Hirano T, Makimoto K. Monitoring of Sleep Indicators, Physical Activity, Pain, and Fatigue in Patients with Systemic Lupus Erythematosus and Relations among These Variables: A Pilot Study. Open Journal of Nursing, 2023; 13: 22-44
  6. Yoshida F, Kato T, Shima Y, Hatano K, Kawashima A, Fukuhara S, Imamura R, Nonomura N. Drug-induced interstitial pneumonia after intravesical Bacillus Calmette-Guerin administration for bladder cancer with scleroderma. IJU Case Rep. 2023; 24;6(2):133-136.
  7. Watanabe A, Shima Y, Takahashi H, Akiyama Y, Kodera M, Jinnin M, Azuma N, Ishii K, Kumanogoh A. Arm heating to relieve Raynaud's phenomenon in systemic sclerosis: A single-arm multicentre prospective clinical trial. Mod Rheumatol. 2023; 33(5):968-974
  8. Shima Y, Watanabe A, Inoue N, Maruyama T, Kunitomo E, Hamano K, Kawanishi T, Takasugi M, Kumanogoh A. Proximal heat stress up-regulates angiopoietin-1 in fingers and reduces the severity of Raynaud's phenomenon in systemic sclerosis: a single-centre pilot study. Mod Rheumatol. 2022;32(2):351-357.
  9. Shima Y. Cytokines involved in the pathogenesis of SSc and problems in the development of anti-cytokine therapy. Cells 2021;10(5):1104.
  10. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP, focuSSced investigators. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020;8(10):963-974.
  11. Tanaka S, Ise W, Inoue T, Ito A, Ono C, Shima Y, Sakakibara S, Nakayama M, Fujii K, Miura I, Sharif J, Koseki H, Koni PA, Raman I, Li QZ, Kubo M, Fujiki K, Nakato R, Shirahige K, Araki H, Miura F, Ito T, Kawakami E, Baba Y, Kurosaki T. Tet2 and Tet3 in B cells are required to repress CD86 and prevent autoimmunity. Nature Immunol. 2020;21(8):950-961.
  12. Shima Y. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. Mod Rheumatol. 2019;29(2):294-301.
  13. Shima Y, Akimoto T, Ike K, Nishino S, Kobayashi Y, Fujiwara Y. A case of rheumatoid arthritis who became able to use ready-made prefilled auto-injectors because of the development of self-assistive devices. Clin Rheumatol Rel Res. 2019;31:204-210.
  14. Shima Y, Kawaguchi Y, Kuwana M. Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy. Mod Rheumatol. 2019;29(1):134-139.
  15. Inoue M, Shiozawa K, Yoshihara R, Yamane T, Shima Y, Hirano T, Makimoto K. Predictors of poor sleep quality in patients with systemic lupus erythematosus. Clin Rheumatol. 2017;36(5):1053-1062.
  16. Morita T, Fujimoto K, Shima Y, Ogata A, Kumanogoh A. Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis. Ann Rheum Dis. 2018;77(9):e56.
  17. Nishide M, Nojima S, Ito D, Takamatsu H, Koyama S, Kang S, Kimura T, Morimoto K, Hosokawa T, Hayama Y, Kinehara Y, Kato Y, Nakatani T, Nakanishi Y, Tsuda T, Park JH, Hirano T, Shima Y, Narazaki M, Morii E, Kumanogoh A. Semaphorin 4D inhibits neutrophil activation and is involved in the pathogenesis of neutrophil-mediated autoimmune vasculitis. Ann Rheum Dis. 2017;76(8):1440-1448.
PAGE TOP